Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 31 % of short-term debt in 2021; threshold 65 %.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2021
AVERROES PHARMA from Sint-Jans-Molenbeek, company number BE0738813960, closed financial year 2021 with a result of € -36,368 after tax. For that financial year AVERROES PHARMA recorded a gross margin of € -23,806 and equity of € -35,369. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2022.
€ -35,369
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -36,368
Profit after tax over the fiscal year.
€ 20,865
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -55,369.
People and assets in 2021
€ 11,927
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,075
Book value of vehicles, furniture and equipment.
Debts at end 2021
None
No bank loans on the last day of the fiscal year.
€ 72,607
Supplier invoices still open on the last day of the fiscal year.
€ 2,796
Taxes, VAT and social contributions still to pay.
Ask about AVERROES PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to AVERROES PHARMA?
What happened at AVERROES PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
AVERROES PHARMA is active according to the CBE. Legal situation: Opening faillissement.
- New annual accounts for financial year 2021: loss of € 36,368. Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Sint-Joost-ten-Node. KBO
Management
Behind AVERROES PHARMA are MOHAMMED KHAYAT SRITAH and OUSSAMA AISSAOUI.
Directors
According to the 2021 annual accounts
MOHAMMED KHAYAT SRITAH
Director
OUSSAMA AISSAOUI
Director
Establishments
Establishment units
Physical locations of this company
Opzichterstraat 184
1080 Sint-Jans-Molenbeek
Merinosstraat 18
1210 Sint-Joost-ten-Node
Active since 6 December 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Sint-Jans-Molenbeek
Same main activity (Detailhandel in farmaceutische producten), 22 active companies in Sint-Jans-Molenbeek, largest first.
PHARMACIE DE LA DUCHESSE DE BRABANT
€ 679,495 gross margin · 2025
€ 634,648 gross margin · 2025
€ 513,090 gross margin · 2025
€ 414,005 gross margin · 2025
€ 352,735 gross margin · 2024
€ 352,674 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- AISSAOUI Oussama(oprichter) 50%
- KHAYAT SRITAH Mohammed(oprichter) 50%
Details
- Company number
- 0738.813.960
- VAT number
- BE 0738.813.960
- Registered office
- Opzichterstraat 184, 1080 Sint-Jans-Molenbeek
- Names & denominations
- AVERROES PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Opening faillissement
- Start date
- 6 December 2019
- Peppol
- Not registered
- Activities · NACE
Detailhandel in farmaceutische producten